It has been previously suggested that the outcome of T-ALL patients could partially predict the response of PDXs to different chemotherapics, including VCR, both in vivo and ex vivo.28 Based on this suggestion, we decided to correlate AKR1C1-3 expression and VCR response separately in the group of PDX-T-ALLs generated from prednisone good responder (PGR) or prednisone poor responder (PPR, commonly stratified as high-risk) patients. This evidence concerns the gene AKR1C1 and acute lymphoblastic leukemia.